Mylan NV’s latest troubles could not come at a worse time.
Two years ago, Mylan was a swaggering drugmaker on the way up, buying up rivals as it grew and diversified.
Then it faced political scrutiny over price hikes for its EpiPen allergy shot and increasing pressure on prices for the generic drugs that are the company’s backbone.
In August, Mylan cut its outlook for next year, and on Tuesday came another blow: Its No. 2 executive was one of the first two top managers accused in an industry-wide civil investigation of colluding in a “sinister” conspiracy to prop up prices.
After reaching an all-time high of US$76.06 in April 2015, its shares have been cut in half and closed on Tuesday at US$35.71, dropping 6.6 percent for the day.
Like other drugmakers, Mylan has been under increasing pressure from regulators at the US Food and Drug Administration (FDA) over the past year.
Taking up US President Donald Trump’s call to reduce drug prices, the FDA has said it will accelerate the approval of copycat drugs that will push prices down further. The agency has said it will specifically target drugs that only have a few generic competitors, trimming the industry’s already thin margins further.
The multi-year civil case against Mylan and 17 other makers of generic pills — with a dragnet that could wrap in other senior drug executives around the industry — could prove damaging.
Not only does it target Mylan president Rajiv Malik, but the alleged conduct in the complaint supposedly helped generic-drug makers preserve their margins and markets, avoiding some of the competition that has already been pressuring the industry.
In their 243-page complaint, 45 US states and Washington said that more than a dozen drugmakers worked together to share the market and avoid a “fight to the bottom.”
At industry conferences, over dinner parties and hundreds of telephone calls, e-mails and text messages, executives would agree to raise or maintain prices for specific drugs in tandem or delineate each company’s market share.
Malik is one of two senior drug executives named in the new complaint, in which the states are seeking to expand an earlier lawsuit alleging price and market fixing.
Mylan, which is also named as a defendant in the case, said it stands behind Malik and will “defend this case vigorously.”
Malik’s lawyer, Robert Cleary of Proskauer Rose LLP, said in a telephone interview that the executive “emphatically and categorically denies the allegations in the complaint” and “is confident he will be completely vindicated.”
The complaint details numerous telephone calls and e-mails between Malik and executives at closely held Indian drugmaker Emcure Pharmaceuticals Ltd and its subsidiary, Heritage Pharmaceuticals, around the time when Heritage launched an antibiotic called Doxy DR.
Mylan — then the only other generic maker with that pill on the market — agreed to give up two large accounts to Heritage, helping Heritage enter the market without putting pressure on prices, the filling said.
“Given direct involvement of executives in this case and the evidence we had implicating them, we felt as a group of antitrust enforcers that it was important to hold these individuals accountable,” Connecticut Assistant Attorney General Joseph Nielsen said on Tuesday on a conference call with reporters.
The civil investigation has run parallel to a criminal probe by the US Department of Justice that has so far led to guilty pleas from two former executives of Heritage, the Emcure subsidiary. The complaint has now expanded from six to 18 companies and 15 drugs.
Malik has worked at Mylan since 2007 and became president in 2012. Previously, he worked at Sandoz and at Ranbaxy Laboratories Ltd. One of Mylan’s senior-most executives, he is a regular speaker on quarterly earnings calls.
The company, which has a legal address in the Netherlands and is run from Canonsburg, Pennsylvania, describes him on its Web site as the leader of “all global commercial and operational activities.”
“Rajiv is easily one of the foremost generic heads out there and is a core part of Mylan leadership,” Evercore-ISI analyst Umer Raffat said.
The troubles might not end at Mylan and Emcure. On the conference call on Tuesday, Connecticut Attorney General George Jepsen suggested that other executives could be drawn in.
“Every time we kick a door in we make new discoveries,” Jepsen told reporters.
The domestic unit of the Chinese-owned, Dutch-headquartered chipmaker Nexperia BV will soon be able to produce semiconductors locally within China, according to two company sources. Nexperia is at the center of a global tug-of-war over critical semiconductor technology, with a Dutch court in February ordering a probe into alleged mismanagement at the company. The geopolitical tussle has disrupted supply chains, with some carmakers reportedly forced to cut production due to chip shortages. Local production would allow Nexperia’s domestic arm, Nexperia Semiconductors (China) Ltd (安世半導體中國), to bypass restrictions in place since October on the supply of silicon wafers — etched with tiny components to
Singapore-based ride-hailing and delivery giant Grab Holdings Ltd has applied for regulatory approval to acquire the Taiwan operations of Germany-based Delivery Hero SE's Foodpanda in a deal valued at about US$600 million. Grab submitted the filing to the Fair Trade Commission on Friday last week, with the transaction subject to regulatory review and approval, the company said in a statement yesterday. Its independent governance structure would help foster a healthy and competitive market in Taiwan if the deal is approved, Grab said. Grab, which is listed on the NASDAQ, said in the filing that US-based Uber Technologies Inc holds about 13 percent of
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday received government approval to deploy its advanced 3-nanometer (3nm) process at its second fab currently under construction in Japan, the Ministry of Economic Affairs said in a news release. The ministry green-lit the plan for the facility in Kumamoto, which is scheduled to start installing equipment and come online in 2028 with a monthly production capacity of 15,000 12-inch wafers, the ministry said. The Department of Investment Review in June 2024 authorized a US$5.26 billion investment for the facility, slated to manufacture 6- to 12nm chips, significantly less advanced than 3nm process. At a meeting with
Taiwan is open to joining a global liquefied natural gas (LNG) program if one is created, but on the condition that countries provide delivery even in a scenario where there is a conflict with China, an energy department official said yesterday. While Taiwan’s priority is to have enough LNG at home, the nation is open to exploring potential strategic reserves in other countries such as Japan or South Korea, Energy Administration Deputy Director-General Chen Chung-hsien (陳崇憲) said. While the LNG market does not have a global reserve for emergencies like that of oil, the concept has been raised a few times —
RSS